Figure 5.

Tenascin-C (TNC) level at baseline is predictive of future tender joint count in rheumatoid arthritis (RA) patients at both 16 to 18 weeks and 54 weeks after commencing infliximab therapy. Serum from RA patients in cohort A at baseline (entry into the trial) was analysed for TNC level by ELISA. TNC levels are shown with practitioner-determined tender joint counts in these patients at 16 to 18 weeks (A) and 54 weeks (B) after receiving infliximab therapy (n = 24). Significance was determined by spearman rank correlation analysis.